Abstract
Thyroid hormones regulate fundamental genes involved in the metabolism, development and homeostasis of vertebrates. The endogenous hormones, L-3, 5, 3-triiodo-L-thyronine (T3) and L-3, 5, 3, 5-tetraiodo-L-thyronine (T4), are of limited use in pharmacological intervention, mainly due to cardiovascular liabilities. There exist two subtypes of thyroid hormone receptors (TR), α and β, unequally distributed in the body. As TRα is most abundant in the heart and most effects of thyroid hormones on the heart are mediated through TRα, a reasonable strategy is the development of TR agonists that either are tissue selective or that interact selectively with TRβ. The prospects for the treatment of metabolic diseases with such ligands are considerable and this review describes the massive efforts of the academic and industrial communities during the last decade. It is, however, the authors view that the development of selective ligands only is in its infancy, an opinion highlighted by the limited chemical structural variation of TR ligands as well as the present lack of TR ligands for the treatment of metabolic diseases in clinical phases.
Keywords: thyroid hormones, thyroid hormone receptors, dyslipidemia, diabetes, hypothyroidism, obesity, atherosclerosis, metabolic diseases
Current Pharmaceutical Design
Title: Thyroid Hormone Ligands and Metabolic Diseases
Volume: 10 Issue: 28
Author(s): Johan Malm
Affiliation:
Keywords: thyroid hormones, thyroid hormone receptors, dyslipidemia, diabetes, hypothyroidism, obesity, atherosclerosis, metabolic diseases
Abstract: Thyroid hormones regulate fundamental genes involved in the metabolism, development and homeostasis of vertebrates. The endogenous hormones, L-3, 5, 3-triiodo-L-thyronine (T3) and L-3, 5, 3, 5-tetraiodo-L-thyronine (T4), are of limited use in pharmacological intervention, mainly due to cardiovascular liabilities. There exist two subtypes of thyroid hormone receptors (TR), α and β, unequally distributed in the body. As TRα is most abundant in the heart and most effects of thyroid hormones on the heart are mediated through TRα, a reasonable strategy is the development of TR agonists that either are tissue selective or that interact selectively with TRβ. The prospects for the treatment of metabolic diseases with such ligands are considerable and this review describes the massive efforts of the academic and industrial communities during the last decade. It is, however, the authors view that the development of selective ligands only is in its infancy, an opinion highlighted by the limited chemical structural variation of TR ligands as well as the present lack of TR ligands for the treatment of metabolic diseases in clinical phases.
Export Options
About this article
Cite this article as:
Malm Johan, Thyroid Hormone Ligands and Metabolic Diseases, Current Pharmaceutical Design 2004; 10 (28) . https://dx.doi.org/10.2174/1381612043382873
DOI https://dx.doi.org/10.2174/1381612043382873 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis of Diabetes in a Diabetic Patients Urine and Blood Using a Combination Electrode with a Ubiquitous Handheld Analyzer
Current Analytical Chemistry COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued) Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Clinical Observation of Liver Chemistry Abnormalities in Asthmatics
Current Drug Safety Benzothiazole Derivatives: Novel Inhibitors of Methylglyoxal Mediated Glycation of Proteins In Vitro
Medicinal Chemistry Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Synthesis and Bioactivities of 2-Azetidinones as Cholesterol Absorption Inhibitors
Letters in Drug Design & Discovery In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects
Current Gene Therapy Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Myocardial Infarction with Non Obstructive Coronary Atherosclerosis: A Case Report
New Emirates Medical Journal High Blood Pressure and the Risk of Stroke
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)